# S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

> **NCT01693419** · PHASE2 · COMPLETED · sponsor: **Hallym University Medical Center** · enrollment: 37 (actual)

## Conditions studied

- Pancreas Neoplasms

## Interventions

- **DRUG:** GES (Gemcitabine, Erlotinib, S-1)

## Key facts

- **NCT ID:** NCT01693419
- **Lead sponsor:** Hallym University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693419, "S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01693419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*